Tekla Life Sciences Investors (HQL)

Tekla Life Sciences Investors at a glance — key fundamentals, SEC filings, insider buying and selling, and earnings dates.

Tekla Life Sciences Investors (HQL) is a Asset Management company based in US with a market capitalization of $604.5M. Revenue declined 0.3% year-over-year and free cash flow was negative at -$2.3M. This page tracks HQL's SEC filings, insider buying and selling, earnings dates, and key fundamentals in one place.

US · IPO May 1, 1992

Valuation

Valuation & price

$17.78as of May 17, 2026· -14.6% vs 52w high

6.0

P/E ratio

Latest-FY diluted EPS

1.18

P/B ratio

Market cap ÷ book equity

Dividend yield

Price — last 12 months

$20.28$16.66$13.05Jul 25Jan 26Jul 26
$12.9652-week range$20.83
Loading valuation history…

Fundamentals

Key fundamentals

$604.5M

Market cap

-0.3%

Revenue growth (YoY)

100.0%

Gross margin

-$2.3M

Free cash flow (USD)

-$75.5K

Net debt

Net cash position

2.9%

Share dilution

2/4

Graham criteria passed

Defensive-investor screen

Financial Services

Sector

Trajectory

Long-term trends

Revenue by year

20162025

$6.3M$86.4M

Free cash flow by year

20162025

$0-$2.3M

Gross margin by year

20212025

86.5%100.0%

Value screen

Graham defensive-investor tests

Computing the scorecard — refreshing any stale inputs…

0

Insider buys · 90 days

0

Insider sells · 90 days

Earnings

Last reported: —

Next expected: not yet scheduled

On the tape

Recent SEC & insider activity

No tracked SEC signals for HQL yet — activity appears here as filings land on EDGAR.

Questions

Frequently asked questions

What is Tekla Life Sciences Investors's market cap?

Tekla Life Sciences Investors (HQL) has a market capitalization of $604.5M.

What is HQL's P/E ratio?

HQL trades at a price-to-earnings ratio of 6.0, based on its latest fiscal-year diluted earnings per share and the most recent cached price.

What is HQL's price-to-book (P/B) ratio?

HQL trades at 1.18 times book value per share.

Are insiders buying HQL stock?

SEC Form 4 filings show no open-market insider buys at Tekla Life Sciences Investors in the last 90 days (0 sells).

Same arena

Related companies in Asset Management

Timeline

Every filing, insider trade & earnings on a price-anchored timeline

Filing Analyzer

Search the actual 10-K / 10-Q text with AI research angles

News

Latest press coverage in one feed

Data: SEC EDGAR filings and cached fundamental data; prices and ratios use the most recent cached quote and statements (may lag by up to a day). Educational and research purposes only. Not investment advice.